secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2026-09-15T19:01:55+00:00
Accession:  0001193125-26-391780
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia shareholders approve reverse stock split, 2026 equity plan, and director election
--------------------------------------------------------------------------------

- Gregory D. Waller elected Class II director with 377,954 for, 105,236 withheld; 776,125 broker non-votes.
- Approved reverse stock split at 1-for-2 to 1-for-10 ratio, board discretion, action required before June 30, 2027.
- 2026 Omnibus Equity Incentive Plan approved; 400,000 shares initial limit, annual 4% reserve increase from Jan 1, 2027.
- Approved issuance of shares upon exercise of Series A-1 Preferred Investment Options from June 12, 2026 private placement.
- Advisory say-on-pay passed; Ramirez Jimenez International CPAs ratified as independent auditor for FY 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000119312526391780/0001193125-26-391780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000119312526391780/rkda-20260910.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-391780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer